SCHEMBL21145694

SCHEMBL21145694

Cc1cccc(C(=O)NN=Cc2cccc(O)c2O)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.62
LMNA P02545 5/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
MEN1 O00255 4/20 0.62
HTT P42858 3/20 0.62
NOX4 Q9NPH5 1/20 0.61
KDM1A O60341 2/20 0.60
MAPT P10636 5/20 0.59
KDM4E B2RXH2 4/20 0.58
POLB P06746 3/20 0.58
ALDH1A1 P00352 1/20 0.58
ALPL P05186 1/20 0.58
ALPI P09923 1/20 0.58
GAA P10253 1/20 0.58
ALPG P10696 1/20 0.58
GFER P55789 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TDP1 Q9NUW8 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22367607 1.00 KMT2A (0.62) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL21145692 1.00 KMT2A (0.62) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL684835 0.91 KDM1A (0.72) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL680226 0.87 CD38 (0.61) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL684185 0.87 CD38 (0.61) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL26974378 0.87 LMNA (0.62) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL685021 0.85 KDM1A (0.61) KMT2ALMNASMN1; SMN2HTTKDM1A
SCHEMBL15127234 0.85 PIK3CG (0.61) KMT2ALMNASMN1; SMN2HTTKDM1A
SCHEMBL14983946 0.85 NOX4 (0.69) KMT2ALMNASMN1; SMN2MEN1HTT
SCHEMBL6749929 0.85 NOX4 (0.69) KMT2ALMNASMN1; SMN2MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2021-11-09 US disclosed
EP-3700935-A1 DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM University Of South Florida (US) 2020-09-02 EP disclosed
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE QINGDAO PRIMEDICINE PHARMACEUTICAL COMPANY, LTD. (CN) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190216753-A1 N-METHYL-D-ASPARTATE RECEPTOR ALLOSTERIC MODULATORS AND METHODS FOR THEIR USE GRIN2A, GRIN3A, GRIN1 KMT2A 585/4885LMNA 4679/4885SMN1; SMN2 951/4885
US-11166924-B2 N-methyl-d-aspartate receptor allosteric modulators and methods for their use GRIN2A, GRIN3A, GRIN1 KMT2A 585/4885LMNA 4679/4885SMN1; SMN2 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.